BNP Paribas Asset Management’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-42,375
Closed -$35.6M 925
2021
Q3
$35.6M Buy
42,375
+8,547
+25% +$8.67M 0.13% 193
2021
Q2
$42.9M Buy
+33,828
New +$38.2M 0.15% 164

Other funds holding CDLX

BNP Paribas Asset Management's CDLX Position: Q4 2021 in Review

BNP Paribas Asset Management sold out of Cardlytics (CDLX) in Q4 2021, closing a stake of 42,375 shares — an estimated $35.6M sold.

BNP Paribas Asset Management first reported a position in CDLX in Q2 2021 and held it in 2 quarters. The position peaked at $42.9M in Q2 2021. 163 funds tracked by Wall St. Rank hold CDLX as of Q4 2021.

  • BNP Paribas Asset Management reported no remaining Cardlytics position as of Q4 2021 after selling out during the quarter.
  • BNP Paribas Asset Management sold 42,375 Cardlytics shares in Q4 2021, an estimated $35.6M.
  • BNP Paribas Asset Management first reported a position in Cardlytics in Q2 2021 and held it in 2 quarters.
  • BNP Paribas Asset Management's Cardlytics position peaked at $42.9M in Q2 2021.
  • 163 funds tracked by Wall St. Rank held Cardlytics as of Q4 2021.

Based on BNP Paribas Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.